Alexis Ketteringham

• NRx share 31.8% vs Nation 26.6% (2024)
• Top 30% YTD FL (8/9/2024)
• Trelegy decile 2 (Q1), Arexvy decile 2 (Q1), Arexvy decile 2 (Q2)

Successfully oversaw the maintenance and growth of the St. Petersburg territory by marketing a blockbuster inhaler while simultaneously launching a groundbreaking adult vaccine to key medical professionals.

• Outperform direct competitor by 25.2% NRx
• 60-70% market share with two highest volume prescribers in territory
• Pinnacle Quarterly Award Winner (Q1 2022)

Account Management: Managed St Petersburg territory representing three products; one being a blockbuster product generating 5 billion in net sales (end of 2022), a top performing biologic and vaccine.

• Achieved 120% of 2020 goal despite global pandemic
• Surpassed peers, achieving the highest number of customer-facing meetings in 2020
• Ranked 6 out 34 Account Managers Top 20%

Managed expansive territory in West Florida, Alabama, and Georgia. Marketed and sold orphan drugs across various medical specialties such as psychiatry, neurology, sleep medicine, pediatrics, ophthalmology, pain medicine, internal medicine, and family medicine. Excellently maintained client relationships while continually seeking new targets to exceed sales quota.